Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Pharma

Overheard at the J.P. Morgan Healthcare Conference

Executives detailed plans to take on more risk, build on advances in life sciences, and expressed optimism in Medicare Advantage, despite missing enrollment targets.

Pharmaceutical giants are shedding business units with an eye toward focusing on their innovative pharma operations and targeted therapeutic areas.

Head of UK and Ireland Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman

Life sciences companies need to be more engaged in building partnerships that promote high-value care.

Global Leader, Health and Life Sciences, Oliver Wyman
Life Sciences Business Leader, Huron

Imagine a future where leveraging our DNA and what we know about it prevents illness and improves care outcomes.

Co-Founder and CEO, Genome Medical, and 2020 Tom Main Health Innovation Mentorship Winner

And How Stakeholders Can, Literally, Save the World

Climate change will be the biggest impact on global health. The healthcare industry may not respond in time.

Director, Marsh & McLennan Advantage Insights
Partner, Health and Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe

New Predictions on COVID-19 Vaccines and Herd Immunity

How COVID-19 case counts and vaccines may get us back to normalcy by June.

Partner and Vice Chairman, Financial Services, Americas, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Partner and CMO, Health and Life Sciences, Oliver Wyman
Managing Partner, Americas, Oliver Wyman
Principal, Health and Life Sciences, Oliver Wyman

Software-only products providing free-standing treatment represent a key healthcare opportunity for incumbents.

Partner, Health and Life Sciences, Oliver Wyman
Principal, Health and Life Sciences, Oliver Wyman

Social distancing may be necessary for two years or more. Here's where remote care comes into play.

Partner and CMO, Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman

Specialty drugs represent an opportunity to better serve patients, but also pose risks.

Partner, Health and Life Sciences, Oliver Wyman
Principal, Actuarial, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman
Director, Marsh & McLennan Advantage, Healthcare

The recent rise of custom-made drugs is already redefining the state of regulation, society, and the economy.

Researcher, PreScouter

Insights in your inbox

Subscribe